Table 2 Predictors of overall and progression-free survival: univariate analysis
Variable | No of Pts | Overall survival | Progression-free survival | |||||
|---|---|---|---|---|---|---|---|---|
Median OS in months | 95% CI | P-value | Median PFS | 95% CI | P-value | |||
Age | ⩽52 Y | 21 | 91 | 3.3–178.7 | 0.029 | 18.0 | 0–58.4 | 0.11 |
>52 Y | 23 | 26 | 19.0–23.04 | 16.0 | 11.3–20.7 | |||
Gender | M | 31 | 35 | 18.1–52.0 | 0.880 | 15 | 10.6–19.4 | 0.29 |
F | 13 | 33 | 16.9–45.1 | 22 | 11.9–33.1 | |||
ISS Stage | I | 14 | 163.0 | – | 0.01 | 48.0 | 0–119.6 | 0.01 |
II | 12 | 24.0 | 8.7–39.3 | 0.05 | 14.5 | 11.1–17.8 | 0.07 | |
III | 17 | 24.0 | 4.7–43.3 | 12.0 | 9.3–14.7 | |||
I+II | 26 | 56.0 | 18.6–93.4 | 21.0 | 12–29.9 | |||
III | 17 | 24.0 | 4.7–43.3 | 12.0 | 9.3–14.7 | |||
DSS Stage | IIIA | 27 | 57.0 | 24.5–89.5 | 0.01 | 22 | 10.1–33.9 | 0.05 |
IIIB | 17 | 24.0 | 3.5–44.5 | 12 | 1.2–23.0 | |||
Median Interval from diagnosis to Tx | ⩽12 | 24 | 56.0 | 25.4–86.6 | 18 | 6.0–30.0 | 0.29 | |
>12 months | 20 | 22.5 | 18.1–26.9 | 0.025 | 16 | 13.8–18.2 | ||
Serum albumin (G/dL) | ⩽3.5 | 20 | 22.0 | 9.3–34.7 | 0.003 | 12.0 | 7.6–16.4 | 0.002 |
>3.5 | 24 | 72.0 | 24.4–119.6 | 28.0 | 0–56.0 | |||
BM plasma cell % | ⩽40% | 26 | 72.0 | 49.8–94.2 | 0.001 | 25.0 | 11.6–38.4 | 0.02 |
>40% | 18 | 24.0 | 16.7–31.3 | 14.0 | 10.8–17.1 | |||
Induction therapy | Novel | 27 | 56.0 | 16.2–95.8 | 0.000 | 22.0 | 10.1–33.8 | 0.01 |
VAD | 11 | 31.0 | 0–89.3 | 16.0 | 4.4–24.6 | |||
Alkylating agents | 6 | 1.0 | – | 1.0 | – | |||
No of regimen | One | 23 | 63.0 | 40.9–85.1 | 0.003 | 29.0 | 0–66.6 | 0.006 |
For induction | >1 | 21 | 22.0 | 11.2–32.8 | 14.0 | 10.0–19.0 | ||
Pre-Tx status | sensitive | 36 | 32.0 | 21.1–42.9 | 0.35 | 18.0 | 10.6–23.3 | 0.09 |
resistant | 08 | 15.3 | 0–54.1 | 14.0 | 7.1–21.0 | |||
Response to Tx | CR | 16 | 91.0 | – | 0.000 | 76.0 | 39.4–112.6 | 0.000 |
others | 28 | 22.0 | 10.7–33.3 | 13.0 | 8.5–17.5 | |||
